Provexis plc (PXS) - Total Liabilities
Based on the latest financial reports, Provexis plc (PXS) has total liabilities worth GBX230.95K GBX (≈ $28.10 USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Provexis plc generate cash to assess how effectively this company generates cash.
Provexis plc - Total Liabilities Trend (2004–2025)
This chart illustrates how Provexis plc's total liabilities have evolved over time, based on quarterly financial data. See PXS total equity for net asset value and shareholders' equity analysis.
Provexis plc Competitors by Total Liabilities
The table below lists competitors of Provexis plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Goldplat PLC
LSE:GDP
|
UK | GBX16.02 Million |
|
Crown LNG Holdings Limited Ordinary Shares
NASDAQ:CGBS
|
USA | $16.20 Million |
|
TUT Fitness Group Inc
V:GYM
|
Canada | CA$533.79K |
|
TTA Holdings Ltd
AU:TTA
|
Australia | AU$594.78K |
|
Tongaat
JSE:TON
|
South Africa | ZAC7.30 Billion |
|
Sino-German United AG
F:SGU
|
Germany | €1.00 Million |
|
Cirata plc
LSE:CRTA
|
UK | GBX4.94 Million |
|
iomart Group plc
LSE:IOM
|
UK | GBX183.30 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Provexis plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Provexis plc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Provexis plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Provexis plc (2004–2025)
The table below shows the annual total liabilities of Provexis plc from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | GBX248.21K ≈ $30.20 |
-19.27% |
| 2024-03-31 | GBX307.45K ≈ $37.41 |
+63.24% |
| 2023-03-31 | GBX188.34K ≈ $22.92 |
+19.27% |
| 2022-03-31 | GBX157.91K ≈ $19.21 |
+4.80% |
| 2021-03-31 | GBX150.68K ≈ $18.33 |
+0.40% |
| 2020-03-31 | GBX150.08K ≈ $18.26 |
+21.87% |
| 2019-03-31 | GBX123.14K ≈ $14.98 |
+37.77% |
| 2018-03-31 | GBX89.38K ≈ $10.88 |
-32.95% |
| 2017-03-31 | GBX133.31K ≈ $16.22 |
+17.20% |
| 2016-03-31 | GBX113.75K ≈ $13.84 |
-0.29% |
| 2015-03-31 | GBX114.08K ≈ $13.88 |
+5.42% |
| 2014-03-31 | GBX108.21K ≈ $13.17 |
-95.61% |
| 2013-03-31 | GBX2.47 Million ≈ $299.92 |
+16.49% |
| 2012-03-31 | GBX2.12 Million ≈ $257.46 |
+275.18% |
| 2011-03-31 | GBX564.00K ≈ $68.62 |
+91.19% |
| 2010-03-31 | GBX295.00K ≈ $35.89 |
+26.07% |
| 2009-03-31 | GBX234.00K ≈ $28.47 |
-35.18% |
| 2008-03-31 | GBX361.00K ≈ $43.92 |
-56.97% |
| 2007-03-31 | GBX839.00K ≈ $102.08 |
+3.97% |
| 2006-03-31 | GBX807.00K ≈ $98.19 |
-14.42% |
| 2005-03-31 | GBX943.00K ≈ $114.74 |
+338.60% |
| 2004-03-31 | GBX215.00K ≈ $26.16 |
-- |
About Provexis plc
Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and di… Read more